Chevy Chase Trust Holdings LLC Has $163.67 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Chevy Chase Trust Holdings LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 229,767 shares of the biopharmaceutical company's stock after selling 8,612 shares during the period. Chevy Chase Trust Holdings LLC owned 0.21% of Regeneron Pharmaceuticals worth $163,670,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of REGN. Trust Co. of Vermont boosted its position in Regeneron Pharmaceuticals by 8.3% during the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company's stock worth $165,000 after acquiring an additional 12 shares during the period. Nvwm LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.4% during the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company's stock worth $1,039,000 after purchasing an additional 14 shares during the period. Moss Adams Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 3.6% during the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company's stock valued at $456,000 after purchasing an additional 15 shares in the last quarter. Westhampton Capital LLC increased its stake in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Westhampton Capital LLC now owns 893 shares of the biopharmaceutical company's stock valued at $939,000 after buying an additional 15 shares during the period. Finally, Howe & Rusling Inc. lifted its position in Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company's stock worth $486,000 after buying an additional 15 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded up $6.40 during mid-day trading on Tuesday, reaching $680.00. The company had a trading volume of 743,097 shares, compared to its average volume of 945,916. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market cap of $74.73 billion, a price-to-earnings ratio of 17.76, a PEG ratio of 2.38 and a beta of 0.08. The company has a 50 day moving average of $704.64 and a 200-day moving average of $891.91. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the business earned $11.86 earnings per share. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Analyst Ratings Changes

Several research firms have recently commented on REGN. Royal Bank of Canada lowered their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 target price on the stock. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Finally, Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.